Skip to main content
Zentek Ltd. logo

Zentek Ltd. — Investor Relations & Filings

Ticker · ZTEK TSXV Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2022-03-14 Regulatory Filings
Country CA Canada
Listing TSXV ZTEK

About Zentek Ltd.

https://www.zentek.com/

Zentek Ltd. is an intellectual property development and commercialization company focused on applying advanced nanotechnology and nanomaterials, specifically graphene, to solve complex challenges in health, safety, and the environment. The company specializes in developing and commercializing next-generation healthcare solutions across prevention, detection, and treatment. Zentek utilizes strategic partnerships to advance its patented nanotechnologies. A key commercialized product is ZenGUARD™, an antimicrobial coating that employs a graphene-silver combination to significantly enhance viral and bacterial filtration performance in applications such as surgical masks and air filters.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Zentek Ltd. reporting on the results of icephobic coating testing, including laboratory and real-world tests, and outlining next steps for further testing and commercialization. It contains no financial statements, regulatory filings, or detailed financial data. It is an operational update on product development and testing results rather than a financial report or regulatory filing. The document is not an earnings release, annual report, or any form of regulatory filing. It is a general corporate announcement about product testing progress and future plans. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2022-03-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Zentek Ltd. has engaged Vimta Labs for clinical research related to a new healthcare product. It discusses the initiation of pre-clinical studies, patent filings, and forward-looking statements. There is no indication of financial data, regulatory filings, or detailed financial reports. The content is an update on company activities and research progress, typical of a general regulatory announcement or news release. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Given the nature and length of the document, it best fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous announcements that do not fit other specific categories.
2022-03-10 English
News release - English.pdf
Regulatory Filings
2022-03-09 English
News release - English.pdf
Legal Proceedings Report Classification · 95% confidence The document is a news release from Zentek Ltd. addressing rumors and allegations related to intellectual property theft and ongoing litigation. It discusses the company's position on the claim, the assessment of risk, and the company's intention to defend itself. There are no financial statements, detailed financial performance data, or regulatory form references. The document is primarily a legal proceedings update and a company statement to clarify rumors. It does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other financial filings. It is best classified as a Legal Proceedings Report (LTR) because it updates on significant lawsuits and legal matters involving the company.
2022-03-09 English
News release - English.pdf
Regulatory Filings
2022-03-08 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing that Zentek has received approval for listing its common stock on the Nasdaq Capital Market. It discusses the listing approval, trading symbols, and expected timing for commencement of trading. There is no financial data, no detailed report, no voting results, no management changes, no earnings information, or other detailed regulatory filings. The document is an announcement of a capital market event (listing approval) rather than a report or detailed financial disclosure. This fits best under Capital/Financing Update (CAP) as it relates to the company's capital market status and financing visibility. The document length is short (3080 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2022-03-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.